Test Price
2,800 AED✅ Home Collection Available
ADA Gene Severe Combined Immunodeficiency (ADA-SCID) Genetic Test in UAE | AED 2,800
Executive Summary & Core Metrics
- Analytical Precision: >99.9% diagnostic sensitivity using ISO‑certified NGS with ACMG variant classification.
- VIP Mobile Phlebotomy: Temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM.
- Post‑Test Clinical Guidance: Dedicated telephone consultation with a genetics specialist to interpret results.
- Insurance Verification: Direct coverage check via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test uses Next‑Generation Sequencing (NGS) with whole‑gene coverage of the ADA locus to detect pathogenic and likely pathogenic variants causing adenosine deaminase deficiency (ADA‑SCID). The assay targets all coding exons, splice junctions, and deep intronic regions, providing single‑nucleotide resolution with >99.9% analytical sensitivity. Results are classified according to ACMG/AMP guidelines and correlated with clinical and immunological findings to enable definitive diagnosis and timely therapeutic intervention (enzyme replacement, hematopoietic stem cell transplant, or gene therapy).
| Characteristic | Our Test | Closest Alternative |
|---|---|---|
| Precision | Single‑nucleotide resolution, >99.9% analytical sensitivity | Enzymatic assay (indirect); lower specificity |
| Method | NGS with bioinformatic variant classification (ACMG guidelines) | Sanger sequencing (targeted, may miss deep intronic variants) |
| Turnaround | 3‑4 weeks with full clinical report | 5‑7 days for enzyme activity; confirmatory sequencing needed |
Physician Insight & Safety Protocols
Clinical Correlation Note from Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
“ADA‑SCID is a pediatric emergency that demands rapid molecular confirmation. This NGS test provides definitive identification of pathogenic variants in the ADA gene, enabling lifesaving decisions such as enzyme replacement therapy or hematopoietic stem cell transplantation. Results must always be interpreted alongside immune cell counts, lymphocyte subsets, and clinical history. Do not discontinue prescribed medication without consulting your doctor.”
Pre‑Test Advisory & Genetic Counseling
All patients must receive pre‑test genetic counseling to understand the implications of a positive result (carrier vs. affected status), potential reproductive risks, and the scope of the test. Counseling is provided by a DHA‑licensed genetics counselor either in person or via telehealth prior to sample collection.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active severe infection requiring inpatient management; inability to provide informed consent; refusal of pre‑test genetic counseling.
- Red Flags – Seek Emergency Care if: Infant/child develops new‑onset respiratory distress, cyanosis, persistent high fever, or severe lymphopenia on recent blood tests.
Patient FAQ & Clinical Guidance
1. What does the ADA gene test detect and why is it ordered?
This NGS test detects mutations in the ADA gene that cause adenosine deaminase deficiency, the most severe form of severe combined immunodeficiency (ADA‑SCID). It is ordered when a newborn or infant presents with recurrent infections, lymphopenia, or positive newborn screening, enabling definitive genetic confirmation and treatment planning.
2. How is the sample collected and what is the turnaround time?
A peripheral blood sample is collected at home by a DHA‑licensed phlebotomist using VIP mobile phlebotomy with temperature‑controlled cold‑chain packaging. Results are delivered within 3–4 weeks, including a comprehensive clinical report with variant interpretation and management recommendations.
3. What do the results mean?
A positive result confirms ADA‑SCID and triggers immediate specialist referral for curative therapy options (stem cell transplant, gene therapy). A negative result rules out ADA deficiency but does not exclude other SCID forms; further immunological workup may be indicated based on clinical presentation and lymphocyte counts.
UAE Regulatory & Data Privacy Adherence
- Data Protection: Compliant with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Security: Adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical Safety & Patient Consent: Aligned with Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring informed consent and clinical accountability.
Clinical & Logistical Metadata
| Test Name | ADA Gene (ADA‑SCID) Genetic Test |
| Price (AED) | AED 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | D81.3 |
| LOINC Code | 21613-5 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians